RecruitingNot ApplicableNCT06627868

Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue


Sponsor

University of Turku

Enrollment

68 participants

Start Date

Nov 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, scientists do not clearly understand the reasons for the decline in brown fat functionality. It is possible that the decline in the availability of the molecule Nicotinamide Adenine Dinucleotide (NAD+), which is central to several metabolic processes, plays a role in the decline in brown fat metabolism. This project will clarify whether NAD+-based molecular-targeted therapies for the enhancement of whole-body insulin sensitivity and brown fat metabolism will be successful in adult humans, which will eventually be an important target for reducing the development of obesity and its comorbidities such as T2DM.


Eligibility

Min Age: 30 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether a molecule called NAD+ (Nicotinamide Adenine Dinucleotide) plays a role in the decline of brown fat function in adults, which may contribute to weight gain and metabolic diseases like type 2 diabetes. Brown fat is a special type of fat that burns energy to produce heat, and its activity tends to decrease with age. Adults aged 30 to 55 with either a normal BMI (18–25) or obesity (BMI 28+) may be eligible, though people with diabetes, thyroid disorders, hypertension, recent infections, or those who cannot undergo PET/CT imaging are excluded. Participation involves specialized imaging scans (PET/CT), blood tests, and possibly a small fat biopsy under local anesthetic to study how the body uses NAD+ in brown fat tissue. This summary was generated with AI assistance to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTNAD+ precursor

NAD+ precursor supplementation (Nicotinamide, Nicotinamide Riboside, or Nicotinamide Mononucleotide)

OTHERPlacebo

Oral placebo daily intake for 6 months


Locations(1)

Turku PET Centre

Turku, Finland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06627868


Related Trials